Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > What we know so far…
View:
Post by canadafan on Jan 22, 2023 6:14pm

What we know so far…

1. The investor presentation was taken down. They have not responded to any enails as to why.
That is a gag order. They can't even reply ";we can't answer that right now". 

2. Over the weekend, I spoke with executives that have bought & sold companies, professional stockbrokers. Other investors.
3. The presentation removal could mean absolutely nothing. The non- reply means everything.
 

Moving forward into speculations.
My original thought was licensing partnership. Onc at last prentation mentioned one partner to cover both Phase 3 ready FDA fast track cancer branches, being breast & pancreatic.

Now if you had to fund 2 trials, why not just buy the whole thing?
They would get the mentioned Pancreatic & breast cancer route, but also the smaller on- going other trials to add to the depth.
don't forget boys & girls , with success the A.N contract has milestone payments & royalties....
for the accounting minded, I hear about $500m in acquired tax loss carry forwards. 

The new owner would get all of that.

price?
for 2 FDA fast track phase 3 ready pathways. In place manufacturing, An existing $$ contract with China.?
I think $1- $3 billion  would be a deal. The $5B number has been thrown around.
should they wait until bracelet/ Pfizer cone if 90 day silence, reveals the encouraging results. Matching or bettering the recent A.N. Report.
that would increase the price yet again.
my opinion, $2Billion , soon.
or much more, if they wait until June.
BTW the gag order could be as simple as part if Pfizer 90 days of exclusive review.
this week ahead.
id be shocked if Onc does not break through & hold well above $2 on NAS.
aks $3++ on TSX ..
That is assuming no news.
great week ahead all.

Comment by Noteable on Jan 22, 2023 8:29pm
$2 Billion is way toooo low especially since pre-clinical drugs like Trillium's CD47 was acquied by Pfiizer for US$ 2.3 Billion and CD47 agents have not proven themselves as being effective. ALSO consider that Phase 2 Immunomedics was acquired by Gilead for US$21 Billion and single agent Pharmacyclics was acquired for US$ 23 Billion. So I don't thin that your out-of-date/scope " ...more  
Comment by canadafan on Jan 22, 2023 8:38pm
The estimate was mine, not my friends. I do not disagree, Well above $5 Billion is possible. Regardless of the price. My point ws about the recent activity. We will knoww the price if/when a B/O happens.
Comment by itntdf on Jan 23, 2023 9:34am
got any spies tracking private jet tail numbers coming into calgary international?  LOL.  maybe bourla's first stop after davos was up there.
Comment by Noteable on Jan 22, 2023 8:43pm
Canadafan, just because your friends bought and sold companies means very little particularly since they appear unqualified to value assets in the new world of lifesciences  immuno-oncology and "precision medicine" . If you say otherwise I will challenge you to prove it! Otherwise what you say is nothing other than a simple, out-of-context, and backward looking irrelevant  ...more  
Comment by m00nsh0ts on Jan 22, 2023 8:50pm
Immunomedics was phase 3, Trodelvy is approved.
Comment by Noteable on Jan 22, 2023 9:07pm
Right .. Phase 3 when aacquired.  https://www.gilead.com/news-and-press/press-room/press-releases/2020/9/gilead-sciences-to-acquire-immunomedics
Comment by Lesalpes29 on Jan 22, 2023 9:14pm
Noteable you can shoot every buyout numbers from the past but in the end it could be 2B. And it's probably enough for all the members of the BOD and for most of the longs here! Have a good week,
Comment by Buckhenry on Jan 23, 2023 9:32am
hmm... what's we know so far... absolutely nothing about a buyout unless ur sitting in the boardroom.  but you pumpers do keep us amused. lets see you have went all the way up to 20B and now we are back down to 2B.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities